Fabre-Kramer Pharmaceuticals Inc., a biopharmaceutical company developing therapies to address unmet needs in psychiatry and neurology, received approval from the FDA for Exxua (gepirone hydrochloride extended-release tablets) for the treatment of major depressive disorder (MDD). Exxua represents a new class of antidepressant with a novel mechanism of action that selectively targets the serotonin 1A receptor, a key regulator of mood and emotion. Exxua has been shown to effectively relieve dep...